What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Internal medicine
Lymphoma, Immunology, Pathology, Leukemia and Cancer research are his primary areas of study.
His Lymphoma research entails a greater understanding of Internal medicine.
His work deals with themes such as Hemophagocytic lymphohistiocytosis, Natural killer cell and Peripheral blood mononuclear cell, which intersect with Immunology.
His work in Pathology tackles topics such as Peripheral T-cell lymphoma which are related to areas like CD19, Neutropenia, Humanized antibody and CD30.
His studies deal with areas such as Myeloid, Chronic active EBV infection, Karyotype and Aggressive NK-cell leukemia as well as Leukemia.
His Cancer research research is multidisciplinary, incorporating perspectives in BCL10, Gene, IL-2 receptor and FOXP3.
His most cited work include:
- Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. (718 citations)
- Genetic variants of IL-13 signalling and human asthma and atopy (420 citations)
- Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients (337 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Lymphoma, Pathology, Cancer research, Internal medicine and Immunology.
His research in Lymphoma intersects with topics in T cell, Leukemia, Epstein–Barr virus and Adult T-cell leukemia/lymphoma.
The Cancer research study combines topics in areas such as Mutation and Gene expression profiling.
He has included themes like Gastroenterology and Oncology in his Internal medicine study.
The concepts of his Immunology study are interwoven with issues in Natural killer cell and Cytotoxic T cell.
Koichi Ohshima has researched Diffuse large B-cell lymphoma in several fields, including Vincristine, Germinal center and Rituximab.
He most often published in these fields:
- Lymphoma (51.71%)
- Pathology (42.83%)
- Cancer research (23.72%)
What were the highlights of his more recent work (between 2018-2021)?
- Lymphoma (51.71%)
- Cancer research (23.72%)
- Internal medicine (23.55%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Lymphoma, Cancer research, Internal medicine, Pathology and Oncology.
His biological study spans a wide range of topics, including BCL6, Epstein–Barr virus and Adult T-cell leukemia/lymphoma.
His work carried out in the field of Cancer research brings together such families of science as Immunohistochemistry, Malignancy, Mutation, T cell and Leukemia.
His Leukemia study integrates concerns from other disciplines, such as Tumor microenvironment and Carcinogenesis.
His studies link Gastroenterology with Internal medicine.
His Central nervous system research extends to Pathology, which is thematically connected.
Between 2018 and 2021, his most popular works were:
- Defective Epstein-Barr virus in chronic active infection and haematological malignancy. (60 citations)
- Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma (51 citations)
- Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling (39 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
Koichi Ohshima mainly investigates Lymphoma, Cancer research, Internal medicine, Leukemia and Adult T-cell leukemia/lymphoma.
Lymphoma is a subfield of Pathology that Koichi Ohshima studies.
His Pathology study incorporates themes from Phenotype and CXCL13.
His Cancer research research incorporates themes from Immune checkpoint, Immunohistochemistry, Mutation, CD79B and RHOA.
His Internal medicine research includes themes of Gastroenterology and Oncology.
His research integrates issues of Tumor microenvironment, Human leukocyte antigen and Kinase in his study of Leukemia.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
